Major Cancer Center Further Advances Oncology Research by Integrating Genomic Data Into Medidata's eClinical Platform
May 23 2018 - 7:30AM
Business Wire
Pancreatic Cancer Research Exemplifies
Increasing Use of Genomic Data for Precision Medicine
Medidata (NASDAQ: MDSO) announced that Memorial Sloan Kettering
Cancer Center (MSK) is using Rave Omics with Biomarker Discovery
for patients with pancreatic cancer, an example of the paradigm
shift in clinical trials through the systematic capture of genomic
data and the application of artificial intelligence algorithms. In
doing so, MSK aims to obtain further actionable insights from the
industry’s only unified eClinical platform, the Medidata Clinical
Cloud®.
Memorial Sloan Kettering Cancer Center is at the forefront of
precision medicine, pioneering the application of genomic biomarker
insights to inform and improve patient treatment in oncology. MSK
will now leverage Medidata Rave Omics in addition to Medidata Rave
EDC for pancreatic cancer research to integrate clinical, genomic
and proteomic data and leverage analytics in this pursuit.
Genomic data is increasingly being collected during clinical
trials and is a critical enabler for more targeted therapies and
groundbreaking discoveries. In fact, data from a third-party study1
highlighted clinical trials with molecular biomarkers have a higher
success rate (25.9%) versus trials without biomarkers (8.4%).
However, traditional workflows often lack a secure technology
platform that can incorporate genomic data with other clinical data
types to return insights around safety and efficacy in real time.
Medidata Rave Omics with Biomarker Discovery provides a suite of
solutions that seamlessly integrates clinical trial and genomic
data, checks data quality and performs exploratory data analyses
related to biomarker discovery using machine learning and advanced
analytics - all within the Medidata Clinical Cloud.
“This project addresses MSK’s need to enhance the
integration of large sets of genomic, transcriptomic, and proteomic
data, with the extensive demographic, clinical and pathologic data
we are collecting as part of our clinical research trials for
pancreatic ductal adenocarcinoma,” said Dr. David Kelsen, Edward S.
Gordon Chair in Medical Oncology, MSK. “The automated integration
of large sets of genomic data from research laboratories
will improve our ability to develop new diagnostic tests for
early detection, and novel therapies, for patients with pancreatic
cancer.”
Through the use of Rave Omics, MSK researchers are able to
centralize the disparate sources of data commonly found in a cancer
trial. By integrating the clinical, genomic and proteomic data of a
trial in a single platform, researchers are able to quickly
identify genomic-driven insights through comprehensive, automated
statistical methods and machine learning. With the use of Rave
Omics, MSK aims to streamline processes and expedite their research
in pancreatic cancer.
“We’re excited to continue our long-term collaboration with MSK
and help world-class researchers discover new pancreatic cancer
treatments,” said Glen de Vries, president and co-founder,
Medidata. “MSK’s use of Rave Omics will automate the integration of
genomic data into clinical research and accelerate biomarker
discovery."
About Medidata
Medidata's unified platform, pioneering analytics, and unrivaled
expertise power the development of new therapies for over 1,000
pharmaceutical companies, biotech, medical device firms, academic
medical centers and contract research organizations around the
world. The Medidata Clinical Cloud® connects patients, physicians
and life sciences professionals. Companies on the Medidata platform
are individually and collaboratively reinventing the way research
is done to create smarter, more precise treatments. For more
information: www.mdsol.com
1 Clinical Development Success Rates 2006-2015: BIO, May
2016
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180523005452/en/
MedidataInvestor:Medidata SolutionsBetsy
Frank, +1
917-522-4620bfrank@mdsol.comorMedia:Medidata
SolutionsErik Snider, +1 646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2024 to May 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From May 2023 to May 2024